Inozyme Pharma (INZY) News Today $1.36 0.00 (0.00%) Closing price 01/17/2025 04:00 PM EasternExtended Trading$1.38 +0.02 (+1.47%) As of 08:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest UpdateInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 3,700,000 shares, a growth of 11.4% from the December 15th total of 3,320,000 shares. Currently, 8.4% of the company's stock are sold short. Based on an average daily volume of 545,100 shares, the short-interest ratio is presently 6.8 days.January 19 at 12:16 AM | marketbeat.comWells Fargo & Company Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock PriceJanuary 15, 2025 | americanbankingnews.comHC Wainwright Forecasts Inozyme Pharma Q1 EarningsJanuary 14, 2025 | americanbankingnews.comInozyme price target lowered to $30 from $43 at Piper SandlerJanuary 13, 2025 | markets.businessinsider.comInozyme Pharma (INZY) Receives a Buy from TD CowenJanuary 13, 2025 | markets.businessinsider.comInozyme Pharma (NASDAQ:INZY) Given New $11.00 Price Target at Wells Fargo & CompanyWells Fargo & Company dropped their price objective on Inozyme Pharma from $14.00 to $11.00 and set an "overweight" rating on the stock in a research note on Monday.January 13, 2025 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Price Target Cut to $30.00 by Analysts at Piper SandlerPiper Sandler cut their price target on Inozyme Pharma from $43.00 to $30.00 and set an "overweight" rating on the stock in a research report on Monday.January 13, 2025 | marketbeat.comWilliston (OTCMKTS:WHCA) versus Inozyme Pharma (NASDAQ:INZY) Head-To-Head SurveyJanuary 13, 2025 | americanbankingnews.com**Inozyme Pharma (NASDAQ:INZY) Announces Positive Interim Data and Program Updates**SAN FRANCISCO, Jan 10, 2025 /PRNewswire/ -- Inozyme Pharma, Inc. (NASDAQ:INZY) revealed favorable results from its recent interim data analysis and provided key updatJanuary 13, 2025 | americanbankingnews.comHC Wainwright Predicts Inozyme Pharma Q1 EarningsInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Inozyme Pharma in a research report issued on Friday, January 10th. HC Wainwright analyst E. White expects that the company will post earnings of ($0.43) perJanuary 13, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY)January 13, 2025 | americanbankingnews.comBrokerages Set Inozyme Pharma, Inc. (NASDAQ:INZY) Target Price at $17.00January 13, 2025 | americanbankingnews.comInozyme price target lowered to $11 from $14 at Wells FargoJanuary 12, 2025 | markets.businessinsider.comInozyme Pharma: Promising Pipeline and Market Potential Supports Buy RatingJanuary 11, 2025 | markets.businessinsider.comInozyme announces interim data from its ENERGY 1 trial, EAP on INZ-701January 11, 2025 | markets.businessinsider.comWedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY)Wedbush reissued an "outperform" rating and issued a $12.00 price target on shares of Inozyme Pharma in a research note on Friday.January 10, 2025 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Price Target Raised to $16.00HC Wainwright boosted their price objective on shares of Inozyme Pharma from $14.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday.January 10, 2025 | marketbeat.comInozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program UpdatesJanuary 10, 2025 | markets.businessinsider.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of "Buy" from AnalystsInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has been assigned an average recommendation of "Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 1-year price objective amoJanuary 10, 2025 | marketbeat.comInozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by AnalystsInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are presently covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price target amoDecember 16, 2024 | marketbeat.comInozyme initiated with an Outperform at Raymond JamesDecember 12, 2024 | markets.businessinsider.comInozyme Pharma (NASDAQ:INZY) Now Covered by Analysts at Raymond JamesRaymond James initiated coverage on shares of Inozyme Pharma in a report on Thursday. They issued an "outperform" rating and a $26.00 target price on the stock.December 12, 2024 | marketbeat.comEventide Asset Management LLC Raises Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)Eventide Asset Management LLC boosted its stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 5.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,134,436 shares of the company's sNovember 29, 2024 | marketbeat.comInozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | globenewswire.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Recommendation of "Buy" from BrokeragesShares of Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) have been given an average rating of "Buy" by the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month prNovember 21, 2024 | marketbeat.comInozyme Pharma to Present at Upcoming Investor ConferencesNovember 11, 2024 | globenewswire.comFY2024 EPS Estimates for Inozyme Pharma Raised by AnalystInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Research analysts at HC Wainwright increased their FY2024 EPS estimates for Inozyme Pharma in a report issued on Wednesday, November 6th. HC Wainwright analyst E. White now anticipates that the company will earn ($1.62) per share for the year, upNovember 8, 2024 | marketbeat.comFY2024 EPS Estimates for Inozyme Pharma Boosted by AnalystInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Research analysts at Wedbush increased their FY2024 earnings estimates for shares of Inozyme Pharma in a report released on Tuesday, November 5th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($November 7, 2024 | marketbeat.comInozyme Pharma’s Q3 2024 Financial and Clinical ProgressNovember 6, 2024 | markets.businessinsider.comInozyme Pharma Receives Buy Rating for Promising Pipeline and Strategic AdvancementsNovember 6, 2024 | markets.businessinsider.comInozyme Pharma’s Strategic and Financial Positioning Bolsters Buy Rating Amid Upcoming Trial MilestonesNovember 6, 2024 | markets.businessinsider.comPromising Developments in Inozyme Pharma’s INZ-701 Drive Buy RecommendationNovember 6, 2024 | markets.businessinsider.comNeedham & Company LLC Reaffirms "Buy" Rating for Inozyme Pharma (NASDAQ:INZY)Needham & Company LLC reissued a "buy" rating and set a $23.00 price objective on shares of Inozyme Pharma in a report on Wednesday.November 6, 2024 | marketbeat.comInozyme Pharma's (INZY) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $14.00 price objective on shares of Inozyme Pharma in a research report on Wednesday.November 6, 2024 | marketbeat.comInozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNovember 5, 2024 | globenewswire.comPiper Sandler Sticks to Its Buy Rating for Inozyme Pharma (INZY)October 29, 2024 | markets.businessinsider.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of "Buy" from AnalystsInozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) has been given an average rating of "Buy" by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year target price amongOctober 27, 2024 | marketbeat.comPromising Clinical Trial Results Justify Buy Rating for Inozyme PharmaOctober 26, 2024 | markets.businessinsider.comOptimistic Outlook on Inozyme Pharma’s INZ-701 Backed by Promising Trial Data and Market PotentialOctober 25, 2024 | markets.businessinsider.comInozyme Pharma (NASDAQ:INZY) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Friday.October 25, 2024 | marketbeat.comInozyme announces ‘positive’ interim data from ongoing Phase 1 SEAPORT 1 trialOctober 25, 2024 | markets.businessinsider.comInozyme Pharma Reports Promising Results in SEAPORT 1 TrialOctober 25, 2024 | markets.businessinsider.comInozyme Pharma Bullish on Treatment for End-Stage Kidney DiseaseOctober 24, 2024 | marketwatch.comInozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701October 24, 2024 | globenewswire.comInozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | globenewswire.comDimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)Dimensional Fund Advisors LP raised its stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 117.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 380,064 shares of the company's stock after buying anOctober 12, 2024 | marketbeat.comMillennium Management LLC Boosts Stock Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY)Millennium Management LLC increased its position in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 154.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,787,947 shares of the company's stock after acquirOctober 10, 2024 | marketbeat.comInozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of DirectorsOctober 7, 2024 | globenewswire.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of "Buy" from BrokeragesShares of Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) have been given an average recommendation of "Buy" by the seven analysts that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelveOctober 2, 2024 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Earns Outperform Rating from WedbushWedbush reissued an "outperform" rating and set a $15.00 price objective on shares of Inozyme Pharma in a research report on Monday.September 30, 2024 | marketbeat.com Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address INZY Media Mentions By Week INZY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INZY News Sentiment▼0.270.49▲Average Medical News Sentiment INZY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INZY Articles This Week▼32▲INZY Articles Average Week Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Monte Rosa Therapeutics News Korro Bio News Neumora Therapeutics News MBX Biosciences News Precigen News Olema Pharmaceuticals News Corvus Pharmaceuticals News Contineum Therapeutics News Chimerix News LifeVantage News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INZY) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
